Lineage Cell Therapeutics (LCTX) Goodwill (2019 - 2026)

Lineage Cell Therapeutics has reported Goodwill for 8 years, with the latest figure at $10.7 million in Q1 2026.

• For the quarter ending Q1 2026, Goodwill changed 0.0% year-over-year to $10.7 million; the trailing twelve-month figure through Mar 2026 stood at $10.7 million (changed 0.0% YoY), and the FY2025 full-year result was $10.7 million, changed 0.0% from the prior year.
• Goodwill for Q1 2026 stood at $10.7 million, roughly flat from $10.7 million in the prior quarter.
• The five-year high for Goodwill was $10.7 million in Q1 2022, with the low at $10.7 million in Q1 2022.
• Historically, Goodwill has averaged $10.7 million across 5 years, with a median of $10.7 million in 2022.
• The largest YoY upside for Goodwill was 0.0% in 2022 against a maximum downside of 0.0% in 2022.
• Lineage Cell Therapeutics' Goodwill stood at $10.7 million in 2022, then changed by 0.0% to $10.7 million in 2023, then changed by 0.0% to $10.7 million in 2024, then changed by 0.0% to $10.7 million in 2025, then changed by 0.0% to $10.7 million in 2026.
• The last three Goodwill figures came in at $10.7 million (Q1 2026), $10.7 million (Q4 2025), and $10.7 million (Q3 2025), per Business Quant data.